Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
about
Assessing Predictive Performance of Published Population Pharmacokinetic Models of Intravenous Tobramycin in Pediatric Patients.Potentiation of Aminoglycoside Activity in Pseudomonas aeruginosa by Targeting the AmgRS Envelope Stress-Responsive Two-Component System.Tobramycin and Beta-Lactam Antibiotic Use in Cystic Fibrosis Exacerbations: A Pharmacist Approach.Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.Treatment option for sepsis in children in the era of antibiotic resistance.Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacinIn vitro Activity of Ceftolozane/Tazobactam Alone or with an Aminoglycoside Against Multi-Drug-Resistant Pseudomonas aeruginosa from Pediatric Cystic Fibrosis Patients.Rifampicin potentiation of aminoglycoside activity against cystic fibrosis isolates of Pseudomonas aeruginosa.Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis.MexXY efflux pump overexpression and aminoglycoside resistance in cystic fibrosis isolates of Pseudomonas aeruginosa from chronic infections.Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients
P2860
Q36933449-8CFD5CA9-3015-4C32-9EC8-9B12247A4BF6Q36933502-EF9981D2-432A-4EA2-96E7-CD28D02FD3BBQ37115654-EC35723F-220B-4237-872C-6EC0F14BDAA6Q38193537-FACDE911-71D2-46D4-A9BA-27EFAE2F54BDQ38246118-6671B834-D6AC-44B1-BF82-DC1D76BC7615Q38634682-7904C5A5-A11B-4CC9-9E7D-2E826F177472Q40413499-2CFFC7F8-2103-463E-A5F6-2D3AA6B116ACQ41993020-A73610B9-6C25-4B6A-BE3C-F542AFC1E014Q45019997-A9CFD74C-E5EF-4B7D-B9BF-1EC591093FB2Q45128908-6611934E-2138-49F0-B43C-D120EF9E9860Q50042713-B597D8AC-7E94-44BC-813A-33BF8591B598Q57913561-ACA8A381-D7E9-45D6-9D3A-498496F75B8D
P2860
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Optimization of anti-pseudomon ...... erbations: V. Aminoglycosides.
@en
type
label
Optimization of anti-pseudomon ...... erbations: V. Aminoglycosides.
@en
prefLabel
Optimization of anti-pseudomon ...... erbations: V. Aminoglycosides.
@en
P2093
P2860
P356
P1476
Optimization of anti-pseudomon ...... erbations: V. Aminoglycosides.
@en
P2093
C Dustin Waters
David C Young
Jeffery T Zobell
Krow Ampofo
Michael G Spigarelli
P2860
P304
P356
10.1002/PPUL.22813
P577
2013-09-02T00:00:00Z